The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: A 12-week double-blind, randomized controlled trial

Journal of Clinical Psychopharmacology

Volumn 34, Issue 3, 2014, Pages 337-343

  Lee, Sheng Yu ^a   Chen, Shiou Lan ^a   Chang, Yun Hsuan ^a   Chen, Po See ^a   Huang, San Yuan ^b   Tzeng, Nian Sheng ^b   Wang, Yu Shan ^a   Wang, Liang Jen ^c   Lee, I Hui ^a   Wang, Tzu Yun ^a,d   Yeh, Tzung Lieh ^a   Yang, Yen Kuang ^a,e   Hong, Jau Shyong ^f   Lu, Ru Band ^a,e  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d Tainan Hospital   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

bipolar II depression; cytokines; memantine; treatment

Indexed keywords

CYTOKINE; FLUOXETINE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LORAZEPAM; MEMANTINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TRANQUILIZER;

ADD ON THERAPY; ADULT; AGITATION; ARTICLE; BEHAVIOR DISORDER; BIPOLAR II DISORDER; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SUICIDE ATTEMPT; THERAPY EFFECT; TREATMENT RESPONSE; YOUNG ADULT; YOUNG MANIA RATING SCALE; ANTAGONISTS AND INHIBITORS; BIPOLAR DISORDER; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; CYTOKINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; LINEAR MODELS; MALE; MEMANTINE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, N-METHYL-D-ASPARTATE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 84900492103     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000109     Document Type: Article

References (65)

1. Akiskal HS, Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am. 1999;22(3):517-534, vii.
2. Angst J, Gamma A, Sellaro R, et al. Recurrence of bipolar disorders and major depression. A life-long perspective. Eur Arch Psychiatry Clin Neurosci. 2003;253(5):236-240.
3. Benazzi F. Bipolar II depression in late life: prevalence and clinical features in 525 depressed outpatients. J Affect Disord. 2001;66(1):13-18.
4. Benazzi F, Akiskal HS. Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania. J Affect Disord. 2003;73 (1-2):33-38.
5. Angst J. The bipolar spectrum. Br J Psychiatry. 2007;190:189-191.
6. Vieta E, Suppes T. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord. 2008;10(1 pt 2):163-178.
7. Spence D. Bad medicine: bipolar II disorder. BMJ. 2011;342:d2767.
8. Rihmer Z. AA mood disorders: epidemiology. In: Sadock BSV, ed. Comprehensive Textbook of Psychiatry. Baltimore, MD: Lippincott Williams & Wilkin; 2004.
9. Akiskal HS. The bipolar spectrum: research and clinical perspectives [in French]. Encephale. 1995;21 spec no 6: 3-11.
10. Angst J, Gamma A, Benazzi F, et al. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord. 2003;73(1-2):133-146.
11. Berk M, Dodd S. Bipolar II disorder: a review. Bipolar Disord. 2005;7(1):11-21.
12. Merikangas KR, Lamers F. The 'true' prevalence of bipolar II disorder. Curr Opin Psychiatry. 2012;25(1):19-23.
13. Judd LL, Akiskal HS, Schettler PJ, et al. The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders? J Affect Disord. 2003; 73(1-2):19-32.
14. Pallanti S, Quercioli L, Pazzagli A, et al. Awareness of illness and subjective experience of cognitive complaints in patients with bipolar I and bipolar II disorder. Am J Psychiatry. 1999;156(7):1094-1096.
15. Vieta E, Gastó C, Otero A, et al. Differential features between bipolar I and bipolar II disorder. Compr Psychiatry. 1997;38(2):98-101.
16. Goldstein BI, Kemp DE, Soczynska JK, et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70(8):1078-1090.
17. Breunis MN, Kupka RW, Nolen WA, et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry. 2003;53(2):157-165.
18. Kim YK, Jung HG, Myint AM, et al. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104(1-3):91-95.
19. Knijff EM, Breunis MN, Kupka RW, et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 2007;9(7):743-753.
20. Kupka RW, Breunis MN, Knijff E, et al. Immune activation, steroid resistancy and bipolar disorder. Bipolar Disord. 2002; (4 suppl 1):73-74.
21. O'Brien SM, Scully P, Scott LV, et al. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90(2-3):263-267.
22. Soderlund J, Olsson SK, Samuelsson M, et al. Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder. J Psychiatry Neurosci. 2011;36(2):114-118.
23. Boufidou F, Nikolaou C, Alevizos B, et al. Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord. 2004;82(2):309-313.
24. Knijff EM, Ruwhof C, de Wit HJ, et al. Monocyte-derived dendritic cells in bipolar disorder. Biol Psychiatry. 2006;59(4):317-326.
25. Bosetti F, Rintala J, Seemann R, et al. Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol Psychiatry. 2002;7(8):845-850.
26. Padmos RC, Hillegers MH, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry. 2008;65(4):395-407.
27. Rapaport MH, Manji HK. The effects of lithium on ex vivo cytokine production. Biol Psychiatry. 2001;50(3):217-224.
28. Brietzke E, Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1355-1361.
29. Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008;23(2):87-94.
30. Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(3):213-235.
31. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225-255.
32. Bauer M, Unutzer J, Pincus HA, et al. Bipolar disorder. Ment Health Serv Res. 2002;4(4):225-229.
33. Beyer JL, Krishnan KR. Volumetric brain imaging findings in mood disorders. Bipolar Disord. 2002;4(2):89-104.
34. Wu HM, Tzeng NS, Qian L, et al. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology. 2009;34(10):2344-2357.
35. Chipana C, Torres I, Camarasa J, et al. Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents. Neuropharmacology. 2008;54(8):1254-1263.
36. Popik P, Skolnick P. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol Biochem Behav. 1996;53(4):791-797.
37. Ribeiro Do Couto B, Aguilar MA, Manzanedo C, et al. Effects of NMDA receptor antagonists (MK-801 and memantine) on the acquisition of morphine-induced conditioned place preference in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(6):1035-1043.
38. Chen SL, Tao PL, Chu CH, et al. Low-dose memantine attenuated morphine addictive behavior through its anti-inflammation and neurotrophic effects in rats. J Neuroimmune Pharmacol. 2012;7(2):444-453.
39. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonistVa review of preclinical data. Neuropharmacology. 1999;38(6):735-767.
40. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry. 1978;35(7): 837-844.
41. 2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin Exp Res. 2004;28(3):374-384.
42. Akiskal HS, Djenderedjian AM, Rosenthal RH, et al. Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. Am J Psychiatry. 1977;134(11):1227-1233.
43. Akiskal HS, Rosenthal RH, Rosenthal TL, et al. Differentiation of primary affective illness from situational, symptomatic, and secondary depressions. Arch Gen Psychiatry. 1979;36(6):635-643.
44. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord. 1998;50(2-3):143-151.
45. Benazzi F. Is 4 days the minimum duration of hypomania in bipolar II disorder? Eur Arch Psychiatry Clin Neurosci. 2001;25:32-34.
46. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
47. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278-296.
48. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
49. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44(4): 1049-1060.
50. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157(5):683-694.
51. Bhardwaj A, Aggarwal BB. Receptor-mediated choreography of life and death. J Clin Immunol. 2003;23(5):317-332.
52. Kapczinski F, Dias VV, Kauer-Sant'Anna M, et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1366-1371.
53. Soczynska JK, Kennedy SH, Goldstein BI, et al. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology. 2009;30(4):497-521.
54. Quan MN, Zhang N, Wang YY, et al. Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model. Neuroscience. 2011;182:88-97.
55. Rogoz Z, Skuza G, Maj J, et al. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology. 2002;42(8):1024-1030.
56. Koukopoulos A, Serra G, Koukopoulos AE, et al. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. J Affect Disord. 2012;136(1-2):163-166.
57. Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol. 2007;30(3):136-144.
58. Zarate CA Jr, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163(1):153-155.
59. Muhonen LH, Lonnqvist J, Juva K, et al. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry. 2008;69(3):392-399.
60. Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1362-1374.
61. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;144(1-2):16-27.
62. Brietzke E, Stertz L, Fernandes BS, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116(3):214-217.
63. Goldberg JF, Perlis RH, Bowden CL, et al. Manic symptoms during depressive episodes in 1, 380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2009;166(2):173-181.
64. Goldberg JF, Garno JL, Leon AC, et al. Association of recurrent suicidal ideation with nonremission from acute mixed mania. Am J Psychiatry. 1998;155(12):1753-1755.
65. Pan W, Kastin AJ. Penetration of neurotrophins and cytokines across the blood-brain/blood-spinal cord barrier. Adv Drug Deliv Rev. 1999; 36(2-3):291-298.